期刊文献+

叶氏狼疮方对狼疮肾炎患者T细胞表面共刺激分子表达谱的影响

下载PDF
导出
摘要 目的了解叶氏狼疮方对狼疮肾炎(lupus nephritis,LN)患者外周血T淋巴细胞表面共刺激分子表达谱有无作用。方法轻中度活动期LN患者15例及健康志愿者10例入选。双色标记流式细胞术检测健康对照和叶氏狼疮方治疗前后的LN患者空腹外周血单个核细胞(PBMCs)中CD3+T细胞表面分子CD28,CD40L,LFA-1a和CTLA-4的表达阳性率。其表达水平与系统性红斑狼疮疾病活动指数(SLEDAI)相关分析采用Pear-son相关分析。3组间比较采用单因素方差分析。结果LN患者外周血T细胞表面CD28、CD40L、LFA-1a和CTLA-4表达阳性率较健康对照组均明显升高(CD28:46.34±12.11vs27.66±4.27,CD40L:21.52±6.91vs6.13±1.44,LFA-1a:9.67±3.07vs4.54±1.12,CTLA-4:9.87±1.93vs4.80±1.56,均P<0.001);狼疮方治疗前后比较,LN患者PBMCs中T细胞表面分子CD40L和LFA-1a表达水平差异有显著性(CD40L:21.52±6.91vs15.81±2.31;LFA-1a:9.67±3.07vs8.07±1.15;均P<0.05),而CD28和CTLA-4表达水平差异无显著性(46.34±12.11vs44.69±9.93,9.87±1.93vs8.96±1.65,P均>0.05)。在相关分析研究中,LN患者外周血T细胞表达CD40L、LFA-1a水平与SLEDAI呈明显正相关(r1=0.667,r2=0.654,均P<0.05),而CD28和CTLA-4水平与SLEDAI水平均无相关性。结论叶氏狼疮方可能通过修正LN个体T细胞表面共刺激分子表达谱异常,诱导LN患者免疫耐受重建。
出处 《广东医学》 CAS CSCD 北大核心 2009年第12期1914-1916,共3页 Guangdong Medical Journal
基金 广东省中医药管理局基金资助项目(编号:1050034)
  • 相关文献

参考文献4

二级参考文献24

  • 1Bombardier C, Gladman DD, Urowiz MB, et al. Derivation of the SLEDAI: a disease activity index for lupus patients. Arthritis Rheum, 1992, 35: 630-640.
  • 2Kuiper-Geertsma DG, Derksen RH. Newer drugs for the treatment of lupus nephritis. Drugs, 2003, 63: 167-180.
  • 3Mok CC, Lai KN. Myeophenolate mofetil in lupus glomerulonephritis. Am J Kidney Dis, 2002, 40:447-457.
  • 4Zandman-Goddard G, Shoenfeld Y. Novel approaches to therapy for SLE. Clin Rev Allergy Immunol, 2003, 25:105-112.
  • 5Foster MH. T cells and B cells in lupus nephritis. Semin Nephrol,2007,27( 1 ) :47 - 58.
  • 6Mok CC. Therapeutic options for resistant lupus nephritis. Semin Arthritis Rheum,2006,36(2) :71 - 81.
  • 7Tam LS,Li EK,Wong CK,et al. Safety and efficacy of leflunomide in the treatment of lupus nephritis refractory or intolerant to traditional immunosuppressive therapy: an open label trial. Ann Rheum Dis,2006,65(3) :417 - 418.
  • 8Tam LS, Li EK,Wong CK, et al. Double- blind, randomized, placebo- controlled pilot study of leflunomide in systemic lupus erythematosus. Lupus, 2004,13 (8) : 601 - 604.
  • 9Morris RE, Huang X,Cao W,et al. Leflunomide (HWA 486) and its analog suppress T - and B - cell proliferation in vitro, acute rejection, ongoing rejection, and antidonor antibody synthesis in mouse, rat, and cynomolgus monkey transplant recipients as well as arterial intimal thickening after balloon catheter injury. Transplant Proc, 1995,27( 1 ) :445 - 447.
  • 10Kessel A, Toubi E. Leflunomide in systemic lupus erythematosus. Harefuah,2002,141 (4) :355 - 357,409.

共引文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部